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T he dual antiplatelet therapy (DAPT) score was developed from the DAPT study 1 to predict benefit or harm of continuing DAPT for an additional 18 months in patients without ischemic or hemorrhagic complications within the first 12 months after percutaneous coronary intervention (PCI). 2 The score was derived using multivariable Cox regression analysis from 37 candidate variables to identify independent predictors of ischemic events-myocardial infarction (MI), stent thrombosis (ST), and major adverse cardiac and cerebrovascular events-and hemorrhagic complications-moderate or severe bleeding according to the GUSTO (Global Utilization of tPA or Streptokinase for Occluded Coronary Arteries) definition. 3 Nine variables that predicted both ischemia and bleeding were excluded, leaving 8 unique variables that predicted ischemia (MI at presentation, prior PCI or MI, history of heart failure or left ventricular ejection fraction <30%, vein graft PCI, stent diameter <3 mm, use of paclitaxel-eluting stents, cigarette smoking, and diabetes mellitus) and 1 unique variable that predicted bleeding (advanced age). The median score was 2, and patients with scores ≥2 in whom DAPT was continued had reductions in the composite rates of MI or ST (P<0.001) and major adverse cardiac and cerebrovascular events (P<0.001) without significant differences in death or bleeding. In contrast, patients with scores <2 treated with continued DAPT demonstrated higher risks of bleeding (P<0.001) and death (P=0.02) without significant ischemic benefits. The DAPT score was validated in the PROTECT (Patient-Related Outcomes with Endeavor Versus Cypher Stenting) randomized trial. 4 The utility of the DAPT score has not been examined in a real-world all-comers setting. We, therefore, examined the performance of the DAPT score among patients enrolled in the all-comers ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with drug-eluting stents) registry. 5 We also sought to determine whether incorporating additional variables known to be predictive of ischemia or bleeding that were not assessed in the original DAPT score might further improve its discrimination or calibration.
METHODS
The ADAPT-DES registry design and principal results have been described in detail. 5 In brief, patients undergoing PCI with DES at 11 centers in the United States and Germany were enrolled in a prospective, multicenter study in which aspirin and clopidogrel inhibition of platelet aggregation after standard loading doses was tested. Consecutive patients undergoing PCI at these sites were enrolled if the procedure was successful, and coronary artery bypass graft surgery was not planned; there were no other clinical or anatomic exclusion criteria. Platelet reactivity was tested with the Verify Now point-of-care assay (Accriva, San Diego, CA), and high platelet reactivity (HPR) on clopidogrel was defined as P2Y12 reaction units >208. 6 DAPT was recommended in all patients for 1 year (with longer duration of use at the discretion of the operator) while aspirin was continued indefinitely. The study was powered to detect significant differences in ST between patients with and without HPR. 5 Institutional review board approval was obtained at each participating study center, and all eligible patients provided written informed consent.
Patients were followed by office or phone visits at 30 days, 1 year, and 2 years from the index PCI. The exact days of DAPT usage in the preceding interval was recorded at each visit. ST events were adjudicated by a committee blinded to platelet function testing results according to the definite or probable Academic Research Consortium criteria. 7 MI events were adjudicated according to the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy) definitions and were categorized as ST-related or non-ST-related. 8 Finally, clinically relevant bleeding was defined as bleeding meeting any of
WHAT IS KNOWN
• The dual antiplatelet therapy (DAPT) risk score was developed from the DAPT trial to inform the optimal duration of DAPT after percutaneous coronary intervention, beyond the 1-year period recommended by guidelines.
• It was not validated in a cohort of all-comers percutaneous coronary intervention patients undergoing percutaneous coronary intervention for various clinical indications. It also did not incorporate variables known to predict risk of bleeding in particular and could not include the extent of platelet inhibition achieved by the DAPT regimen. 
WHAT THE STUDY ADDS

Analysis Plan and Statistical Methodology
We calculated the DAPT score in patients who survived without ischemic and hemorrhagic complications and were maintained on DAPT 1 year after enrollment in ADAPT-DES. Clinical outcomes were examined according to whether DAPT was continued between 1 and 2 years after enrollment and by the previously recommended DAPT score cutoff points (<2 versus ≥2 Calibration was considered adequate if P HL >0.05. Cox proportional hazards regression modeling was used to assess the independent relationship of each of the individual components of the DAPT score for both ischemic (MI or ST) and hemorrhagic events between 1 and 2 years after PCI, further accounting for the daily use of DAPT between 1 and 2 years as a timeadjusted covariate, presenting information on time to event as hazard ratio (HR). We then repeated the analysis for the prediction of ischemic events after adding HPR on clopidogrel (as a dichotomous value) to the model (which was shown to predict MI and ST in the original report from the ADAPT-DES study) 5 and for the prediction of bleeding events after adding HPR on clopidogrel (which inversely correlated with bleeding in ADAPT-DES) 5 and 2 additional covariates historically known to predict bleeding which were not collected in the DAPT trial: baseline hemoglobin and warfarin use 1 year after PCI. 12, 13 We calculated the net reclassification index (NRI) and relative integrated discrimination increment (rIDI) with these new parameters to determine whether they improved the accuracy of the models based solely on the DAPT score variables.
14 Categorical variables were compared by the χ 2 or Fisher exact test. Continuous variables are presented as means±SD or medians with interquartile range and were compared by ANOVA. A 2-sided α of 0.05 was used for all statistical testing. Analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC). The data, analytic methods, and study materials are proprietary to the sponsor and will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
Patients, Events, and the DAPT Score
Among the 8582 patients enrolled in ADAPT-DES, 5397 qualified for the present analysis; 478 were excluded because of death before 1 year, 1262 were excluded because of noncompliance with DAPT during the first year (unlike the derivation cohort for DAPT), and 1445 were excluded because of ischemic or hemorrhagic events occurring within the first year. Among the 5397 study patients, 3617 (67.0%) remained on DAPT beyond 1 year after PCI, for a median 336 days (80, 365 days) between 1 and 2 years. The median (interquartile range) DAPT score was 1 (0, 2), range, −2 to 8. Baseline characteristics according to DAPT score <2 versus ≥2 are shown in Table 1 . Patients with lower DAPT scores were older and had less severe coronary artery disease and higher left ventricular ejection fraction. They were more often women, more often presented with stable angina, less frequently had diabetes mellitus, and were less likely to continue DAPT without interruption through 2 years.
No patient withdrew consent between 1 and 2 years from enrollment, and only 5 patients (0.1%) were lost to follow-up. Between 1 and 2 years, ischemic (MI or ST) and hemorrhagic events occurred in 75 (1.5%) and 124 (2.3%) patients, respectively. Patients with higher versus lower DAPT scores (≥2 versus <2) had higher 1-to 2-year rates of MI or ST ( 
Discrimination and Calibration of the DAPT Score Without and With Additional Covariates
For the prediction of MI or ST, bleeding, and death, a DAPT score ≥2 had sensitivities of 57%, 41%, and 56%, respectively; specificities of 58%, 57%, and 58%, respectively; positive predictive values of 1.9%, 2.2%, and 2.1%, respectively; and negative predictive values of 99%, 98%, and 99%, respectively. As a continuous variable, the DAPT score had good discrimination for the composite rate of MI or ST between 1 and 2 years (C statistic=0.71) and adequate calibration (P HL =0.41). As shown in the Figure, the addition of HPR did not significantly improve discrimination for these ischemic events (C statistic=0.71; P=0.82), but it did improve the NRI (25.5%; P=0.03) and rIDI (38.2%; P=0.009). The DAPT score was moderately predictive of bleeding (C statistic=0.62) and had adequate calibration (P HL =0.11). The addition of HPR and the other bleeding correlates (but not HPR alone) did not improve the discrimination for bleeding (C statistic=0.66; P=0.06) but improved the NRI (33.7%; P=0.003) and rIDI (29.1%; P=0.0001).
The DAPT score had moderate discrimination for death between 1 and 2 years (C statistic=0.61) and adequate calibration (P HL =0.52). Adding HPR did not improve discrimination (C statistic=0.64; P=0. 11 
Multivariable Models
Occurrence of the composite ischemic event rate of MI or ST between 1 and 2 years was significantly associated with prior MI or PCI, prior graft PCI, diabetes mellitus, and peripheral arterial disease (Table 3) . Among the original DAPT score components, only peripheral arterial disease was an independent predictor of bleeding between 1 and 2 years (Table 4) . After adding the additional variables, lower baseline hemoglobin and oral anticoagulation use 1 year after PCI were associated with bleeding, along with Values are % (n/N), median (first quartile, third quartile), or mean±SD. DAPT indicates dual antiplatelet therapy; and PCI, percutaneous coronary intervention.
*Hemoglobin <13 g/dL in men and <12 g/dL in women. †By protocol, all patients were on DAPT continuously through 1 year.
presentation with acute coronary syndromes and use of small diameter stents. Finally, increasing age, smoking, diabetes mellitus, use of the TAXUS stent, and chronic kidney disease were independently associated with all-cause death while continued DAPT was protective (Table 5) . When HPR, baseline hemoglobin, and continued warfarin use were added, diabetes mellitus no longer predicted mortality while lower baseline hemoglobin did.
DISCUSSION
The principal findings of the present study are as follows: (1) In patients who were event-free and compliant with DAPT at 1 year after PCI in the all-comers ADAPT-DES registry, the DAPT score had good discriminatory ability to predict ischemic events (MI or ST) and moderate discriminatory ability to predict bleeding events between 1 and 2 years. Overall, the rate of adverse events was low; (2) the addition of HPR on clopidogrel after PCI did not improve the discrimination of the DAPT score for ischemic events although the NRI and rIDI were improved; (3) the addition of HPR on clopidogrel, baseline hemoglobin, and ongoing warfarin use at 1 year marginally improved the discrimination of the DAPT score for prediction of hemorrhagic events between 1 and 2 years after PCI, and the NRI and rIDI were also improved; and (4) after adjusting for baseline covariates, continued DAPT use beyond 1 year compared with aspirin alone showed a trend toward reduced MI or ST, was not significantly associated with increased bleeding, and was associated with reduced all-cause death. Increasing the potency or duration of antithrombotic or antiplatelet agents tends to produce offsetting effects by reducing adverse ischemic events at the cost of increased hemorrhagic complications. Efforts to identify patients who may benefit from prolonged DAPT use after PCI based on their relative risks for ischemic and bleeding events is a laudable goal as both types of adverse outcomes have been strongly associated with subsequent mortality. 9, 15 Relevant to the present analysis, we previously demonstrated that ST, MI, and major bleeding were independently associated with increased mortality after PCI in ADAPT-DES (HR, 3.48, 4.52, and 4.17, respectively). In the randomized DAPT trial, continuing clopidogrel or prasugrel in addition to aspirin in a broad spectrum of patients who were event-free at 1 year after PCI for an additional 18 months resulted in reduced rates of MI, ST, and major adverse cardiac and cerebrovascular events, but increased major bleeding, with a borderline increase in all-cause mortality. 1 Palmerini et al 16 used a frequentist pairwise meta-analytic approach to cull data from 10 trials (31 666 patients) and compared different durations of DAPT, ranging from 3 to 36 months. They found that shorter DAPT duration was associated with lower mortality (HR, 0.82; 95% CI, 0.69-0.98; P=0.02), predominantly because of lower noncardiac mortality and major bleeding, despite higher rates of MI and ST. These results were confirmed in a Bayesian analysis without informative priors. 17 The DAPT score was subsequently developed to identify patients who might have a favorable net clinical benefit of prolonged DAPT. 2 In their internally derived analysis, patients with a DAPT score ≥2 benefitted from prolonged DAPT by reductions in ischemic events with neutral effects on bleeding and mortality. Conversely, patients with DAPT scores <2 treated with continued DAPT demonstrated net harm, with higher risks of bleeding and mortality without significant ischemic benefits.
The present study confirms and extends these results by examining the utility of the DAPT score in all-comers real-world population. The DAPT score C statistic for ischemia of 0.71 in ADAPT-DES was similar to that seen in the randomized DAPT study (0.70), with adequate calibration. The DAPT score C statistic for bleeding in ADAPT-DES was lower than in the DAPT study (0.62 versus 0.68, respectively), but calibration was adequate. Adding additional covariates not captured in the DAPT score (HPR on clopidogrel, baseline hemoglobin level, and ongoing warfarin use) improved the discrimination for bleeding but not for ischemia, and the predictive accuracy of both models was enhanced as reflected in improved NRI and rIDI indices. Moreover, in the present study, all-cause mortality was similar in patients with DAPT scores <2 versus ≥2. The accuracy of the DAPT score for all-cause death was somewhat improved by adding HPR on clopidogrel and the additional bleeding covariates.
These data may explain why prior studies attempting to personalize the duration of DAPT in cohorts at highrisk for ischemia and low-risk for bleeding have at best been neutral. Yoshikawa et al 18 recently reported that among 12 223 Japanese patients free of ischemic and hemorrhagic events at 13 months after DES, a DAPT score ≥2 compared with <2 was associated with a higher rate of ischemic events between 13 and 36 months Model 1 uses the DAPT score covariates only, also adjusted for DAPT use between 1 and 2 y. Model 2 also incorporates high platelet reactivity (HPR) on clopidogrel, a variable not collected in the DAPT trial. CAD indicates coronary artery disease; DAPT, dual antiplatelet therapy; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
*Denotes time-dependent variable. †Defined as creatinine clearance <60 cc/min.
(P=0.002), with a trend toward lower rates of bleeding (P=0.07); however, in a propensity-matched analysis, on-DAPT versus off-DAPT status at 13 months was not significantly associated with subsequent ischemia or bleeding either in the high or low DAPT score groups. Several other studies have focused on patients with prior MI. In the DAPT trial, prolonged DAPT (compared with aspirin alone) reduced major adverse cardiac and cerebrovascular events between 12 and 30 months in patients presenting with MI (3.9% versus 6.8%) but not in those without MI (4.4% versus 5.8%; P INT =0.03) while increasing bleeding in both groups. 19 In a nonrandomized British study of 18 307 MI survivors in which electronic health records were used to catalog events, 20 independent predictors of ischemic risk and 18 predictors of hemorrhagic risk were identified, allowing the authors to create a risk score with a C statistic of 0.75 for the 3-year risk of ischemic events and 0.67 to 0.72 for bleeding according to various definitions. 20 A net clinical benefit of prolonged DAPT was suggested in 63% to 99% patients depending on the relative weights applied to ischemic and bleeding events; however, in the randomized PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events [Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin), DAPT use with ticagrelor compared with aspirin alone in patients with MI 1 to 3 years before enrollment reduced ischemic event rates but substantially increased bleeding with a net neutral effect on mortality. 21 Notably, in the present study, after adjustment for differences in baseline covariates (including the components of the DAPT score and additional ischemic and bleeding-related covariates), continued DAPT use after 1 year was associated with reduced all-cause death and a trend toward fewer MI or ST events without significantly increased bleeding. Although these results must be considered hypothesis generating because ongoing DAPT use was not randomized, the ADAPT-DES allcomers population was substantially higher risk than the populations enrolled in most randomized trials, with high rates of patients with renal insufficiency, extensive coronary artery disease, and other comorbidities.
We recognize the inherent limitations of the present analysis and inferences. Inherent to the use of this score, important variables that predict both ischemic and hemorrhagic events were excluded from the models. Although the DAPT trial randomized patients to continued DAPT beyond 1 year, we had to adjust for DAPT continuation in the ADAPT-DES registry. Even though a time-dependent analysis was used for this purpose, unmeasured confounders may have added imprecision to the estimates. Furthermore, the comparisons were not powered to detect significant Model 1 uses the DAPT score covariates only, also adjusted for DAPT use between 1 and 2 years. Model 2 also incorporates high platelet reactivity (HPR) on clopidogrel, baseline hemoglobin, and warfarin use at 1 year, variables not collected in the DAPT trial. CAD indicates coronary artery disease; DAPT, dual antiplatelet therapy; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
*Denotes time-dependent variable. †Defined as creatinine clearance <60 cc/min. differences in relatively rare events. Follow-up was truncated at 24 months, as opposed to 30 months in the DAPT trial. A large number of patients were excluded because of noncompliance with DAPT in the first 12 months. Logistic regression and Cox proportional hazards models are limited by assumptions of linearity, proportional baseline hazard rate, and loss to follow-up. We also emphasize this analysis was exploratory and did not adjust for multiple hypothesis tests. Offsetting these limitations was the prospective nature of the study, with inclusion of a true all-comers population with few exclusion criteria, and source document collection with adjudication of adverse events. Moreover, no other study has had HPR data available to consider as a risk factor. We conclude that in the ADAPT-DES registry, the DAPT score had modest utility to determine which eventfree patients at 1 year after PCI might benefit from an additional 1 year of DAPT. Adding additional risk factors for ischemia and bleeding, such as HPR on clopidogrel, baseline hemoglobin, and ongoing warfarin use, variables that are not elements of the DAPT score, modestly strengthened the models but not to the extent where their predictive accuracy was high. Other risk markers for adverse ischemic and hemorrhagic events need to be identified to optimize antiplatelet therapy duration decisions after PCI in individual patients.
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*Denotes time-dependent variable. †Defined as creatinine clearance <60 cc min.
